research activities

research activities

bullet
patents

Patent No. KR10-1211902
Non-irritating ophthalmic nano-emulsion composition comprising cyclosporine
Patent No. KR10-1134340
A eye-drop composition for preventing or treating ocular diseases
Patent No. KR10-1182582
A Method for preparing a purified extract of Lonicera japonica Thunberg and the composition comprising the same for treating and preventing sepsis and septic shock
Patent No. KR10-1090672
A method for preparing purified fractions of Lonicerae Flos showing potent anti-inflammatory activity and the composition comprising the same for preventing and treating inflammatory diseases
Patent No. KR10-1070600
Composition comprising the purified fraction isolated from Bee Venom for preventing and treating of degenerative brain diseases
Patent No. KR10-1021654
A pharmaceutical preparation for treating gastrointestinal disease comprising sodium alginate mixture as an active ingredient and the method for preparing the same
Patent No. KR10-0860272
Method for extraction and purification of effective component from agrimonia pilosa ledeb and crude drug composition containing extract thereof for prevention and treatment of sample
Patent No. KR10-0786122
Composition effective for prevention and treatment of obesity which contains crude drug extract
Patent No. KR10-0853104
Method for detecting proteins using the SPR chip on which dendrimer is attached
Patent No. KR10-0741644
Method for extracting astaxanthin using surfactant from green algae
Patent No. KR10-0649457
Injectable composition comprising ginkgo biloba leaf extract and manufacturing method thereof
Patent No. KR10-1021654
A pharmaceutical preparation for treating gastrointestinal disease comprising sodium alginate mixture as an active ingredient and the method for preparing the same
Patent No. KR10-0836528
Process of manufacturing itopride hydrochloride
Patent No. KR10-2009-0044995
Composition comprising the purified fraction isolated from Bee Venom for preventing and treating of degenerative brain diseases
Patent No. KR10-0980819
The composition comprising complex herbal extract as an active ingredient and the preparation method thereof
Patent No. KR10-2009-0063514
A method for preparing purified fractions of Lonicerae Flos showing potent anti-inflammatory activity and the composition comprising the same for preventing and treating inflammatory diseases
Patent No. KR10-2007-0019080
Tablet containing sibutramine free base and manufacturing method thereof

bullet
Project

>Development of natural bee venom based natural medicine for Parkinsonism treatment.
>Development of a new natural medicine of lonicer flower to treat septicemia and it shock treatment
>Development of natural substance-based fatty liver medicine
>Development of bedsore medicine using recombined protein
>Development of new-formulated cyclosporine product for dry-eye treatment
>Adenosine A3 acceptor agonist for ischemia stroke treatment

bullet
pipeline

diagram
Development of Parkinsonism medicine

The medicine has melatin and adolapin, chief ingredients of bee venom, and induces the secretion of adrenaline to improve exhaustion. In addition, the medicine increases the concentration of cortisone, which is a body pain substance. This enhances the anti-flammatory effect on nerve cells, and eases the exhaustion symptom due to degenerative cerebropathia.
As a result of pre-clinical trials, natural bee venom protects dofine nerve cells, and has a direct treatment effect on Parkinsonism by suppressing abnormal rotating movement due to brain cell damage. A clinical trial for manufacturing is under way.

Development of stroke medicine

The natural stroke medicine under research along with the Dongguk University team led by Professor Yonggi Park, School of Medicine at Korea University, and School of Pharmacy at Chungnam University showed that mBHT, the stroke treatment substance, has been effective in suppressing ischemic stroke and increasing life rate in animal models of stroke and ischemic stroke. The research team also found the effect of protecting against nerve cell elimination in cerebral infarction. Currently the second phase of clinical trials is under way with the goal of the product release by the second half of 2014.

Development of septicemia treatment

Huons is developing a new natural substance-based medicine to treat septicemia and its shock as part of the Metropolitan Chungcheong Economic Leading Industry project. A co-research with Chungbuk University and Sungkyunkwan University is currently under way by using animal models similar to clinical septicemia. The candidate substance has shown its effectiveness in improving life rate, suppressing functional imperfection of body organs, and suppressing inflammatory reaction of the animals experimented. Clinical trial is under way, and if successful in product release, the medicine is expected to be available to not only treating septicemia, but also its preventive treatment with the safe natural substance with hardly any toxicity or side effects.

Development of fatty liver treatment

Through the assignments for Seoul and educational-industrial cooperation of Chungcheongbukdo, we have carried out non-clinical and safety effect tests for the alcoholic/non-alcoholic fatty liver animal models in suppressing lipoidosis and neutral fats between tissues. We have also confirmed that the result improved liver ALT levels, and that is effective for liver damage such as fatty liver diseases.
Huons will start clinical tests in fatty liver treatment development. After succeeding, we are sure that the innovative medicine made of natural substances will be effective and low in side effects.

Development of bedsore treatment

3~4 period pressure sores are requiring professional care, treatment of pressure ulcers but effective step is a nonexistent state. Huons Company has been developing human-derived recombinant polypeptide as a pressure ulcer treatment through technology transfer and a clinical stage is now.
In preclinical studies, human-derived recombinant polypeptide found to be effective to less than amount of 200 times compared to treatment with the growth factor used clinically in the field of chronic wounds or sores recently. In the future, it is evaluated as high-value materials and utilized in the chronic pressure sores.

To the first Open CYBERTOUR when you clicked Open Commercial video when you clicked